About us
A biotechnological company focused on developing new drugs from CIMA (Center of Applied Medical Research) of the University of Navarra.
PIPELINE
An extensive pipeline for several diseases in Hepatology, Gene therapy, Oncology and Cardiovascular were developed so far. Three products are already in clinical phase. It is expected a new product reaching clinical trials every year.
RESEARCH AND PRODUCTS
The goal of the company is to develop the patented products to clinical proof-of-concept and to forge partnerships with other biopharmaceutical companies in order to complete clinical development and commercial launch.
INVESTORS
Some of the most important companies and financial institutions in Spain trust in the economic potential of Digna Biotech and invest in our company.
NEWS
|
14-11-2011 Digna Biotech regains all rights to Disitertide (P144) to treat skin conditions |
|
21-09-2011 FDA Grants Cardiotrophin-1 Orphan Drug Status for Acute Liver Failure Treatment |
|
13-09-2011 Cardiotrophin 1 shows promising results for treatment of obesity and metabolic syndrome |
Newsletter
Would you like to receive updates about Digna Biotech? Sign up for our newsletter.